Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer

BACKGROUND: Treatment response biomarkers are urgently needed for castration-resistant prostate cancer (CRPC). Baseline and post-treatment circulating tumor cell (CTC) counts of ≥5 cells/7.5 ml are associated with poor CRPC outcome. OBJECTIVE: To determine the value of a ≥30% CTC decline as a treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorente, David, Olmos, David, Mateo, Joaquin, Bianchini, Diletta, Seed, George, Fleisher, Martin, Danila, Daniel C., Flohr, Penny, Crespo, Mateus, Figueiredo, Ines, Miranda, Susana, Baeten, Kurt, Molina, Arturo, Kheoh, Thian, McCormack, Robert, Terstappen, Leon W.M.M., Scher, Howard I., de Bono, Johann S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568108/
https://www.ncbi.nlm.nih.gov/pubmed/27289566
http://dx.doi.org/10.1016/j.eururo.2016.05.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568108/
https://www.ncbi.nlm.nih.gov/pubmed/27289566
http://dx.doi.org/10.1016/j.eururo.2016.05.023

Ejemplares similares